Hidradenitis suppurativa is a chronic, inflammatory, and often painful skin disease that causes recurring boil-like lumps that may burst into open wounds and cause irreversible scarring, often in the most intimate parts of the body. There are only a few treatment options available for this disease, such as AbbVie's Humira and Novartis' Cosentyx, which affect approximately 1 in 100 people. However, these treatments often offer insufficient relief.
The stock we are bringing to your attention today is that of Avalo Therapeutics Inc. (AVTX), a clinical-stage biotechnology company developing a drug for hidradenitis suppurativa.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.